Back to top

Omada Health guidance ‘could raise questions,’ says Canaccord

Canaccord views Omada Health’s (OMDA) Q2 report as strong but says the company’s guidance “could raise questions.” The Q3 and Q4 revenue and adjust...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE: